Molecular cloning of the bovine prolactin receptor and distribution of prolactin and growth hormone receptor transcripts in fetal and utero-placental tissues

Cloning, sequencing and functional analysis of a truncated cDNA encoding red deer prolactin receptor: an alternative tyrosine residue mediates beta-casein promoter activation

This study reports the isolation and in vitro characterisation of a truncated cDNA encoding the red deer long form prolactin receptor. The cDNA sequence predicts a protein of 557 amino acids which differs from the rat sequence by a 3' truncation of the cytoplasmic domain located 34 residues before the stop codon. The deer sequence shares the regions of homology which are important for maintenance of structural and functional integrity, high affinity binding and signal transduction. However, the truncated deer receptor lacks the most C-terminal tyrosine residue in the intracellular domain which is believed to be essential for activation of the beta-casein promoter. Transfection studies of the cervine cDNA into human 293 fibroblast cells confirmed the expression of a receptor that has high affinity binding to ovine prolactin (Ka = 0.65 x 10(9)M(-1) and Bmax = 548.6 fmol/mg protein). Co-transfection of CHO cells with expression vector encoding the cervine prolactin receptor cDNA along with a fusion gene containing the promoter region of beta-casein followed by beta-luciferase coding sequence led to 8.13 +/- 0.13-fold induction of luciferase enzyme activity in the presence of 400 ng/ml ovine prolactin. This was comparable to fold induction observed with the wild type long form rat prolactin receptor (6.37 +/- 0.48); macaque growth hormone receptor was without effect. Western blot analysis demonstrated tyrosine phosphorylation of the cervine receptor and the associated kinase Jak2 following stimulation with prolactin. This confirms that the cervine cDNA although truncated is fully functional and that Jak2 and an alternative tyrosine residue in the intracellular domain are involved in the signalling pathway leading to activation of the beta-casein promoter. Northern blot analysis provides evidence that the prolactin receptor in the liver is encoded by transcripts of approximately 2.5 and 3.5 kb. Comparison of Northern blots of different deer species suggests that the receptor is conserved amongst the Cervidae. Northern blot analysis of red deer testis suggests that this species expresses a second form of the receptor, encoded by a transcript of 1.7 kb, which may correspond to a smaller receptor form or a binding protein.

Modification of prolactin receptor (PRL-R) expression by PRL in the mouse liver: estimation of the ratio of two forms of PRL-R mRNAs by "one-sided competitive PCR"

We developed new means of measuring the ratio of the short to the long form (S/L ratio) of the mouse prolactin receptor (mPRL-R) cDNA by PCR using a primer common to the two forms and two specific primers. A means of estimating the amount of mPRL-R cDNA by competitive PCR was also established. We confirmed that these procedures were valid, since the S/L ratio of standard DNA was unaltered by one-sided cPCR amplification under the following conditions: the ratio was between 0.1 and 4, and the amount of cDNA was between 10(3) and 10(7) molecules/tube. The result of one-sided cPCR showed that the short form was dominant in the mouse liver, while the long form was dominant in other tissues. In addition, pituitary grafting increased the S/L ratio in the liver, implying that prolactin down-regulated the functional long form of PRL-R and lowered tissue sensitivity to prolactin itself by modifying the post-transcriptional regulation of PRL-R.

Selective modification of recombinant bovine placental lactogen by site-directed mutagenesis at its C terminus

Five recombinant analogues of bovine placental lactogen (bPL) ((bPL(S184H), bPL(S187A), bPL(S187F), bPL(T188F), bPL(T188F,I190F)) were prepared, expressed in Escherichia coli, and purified to homogeneity. Circular dichroism analysis revealed no or minor structural changes, except in bPL(T188F,I190F). Binding and biological activities of bPL(T188F,I190F) were almost completely abolished, whereas bPL analogues mutated at position 187 retained their full activity. Point mutation T188F resulted in selective modification; binding to somatogenic receptors, their extracellular domains (ECDs), and to bPLR in the endometrium as well as somatogenic receptor-mediated biological activities were reduced or abolished, whereas binding to lactogenic receptors, their ECDs, and subsequent biological activity was fully or almost fully retained. This selective modification most likely results from a steric hindrance induced by a bulky Phe-188 chain of bPL which interacts with the Arg-43 of the human or Leu-43 of the non-human GHRs. Point mutation S184H abolished the interaction with hGHR, most likely due to the unfavorable charge-charge interaction, possibly accompanied by steric hindrance between Arg-43 of the receptor and the newly introduced His-184 and possible interference with the putative interaction between the alkyl portion of Thr-188 and Lys-185 of bPL with Trp-104 of hGHR. In contrast, bPL(S184H) retained its capacity to interact with nonhuman GHRs. Decrease in the biological activity of bPL(S184H) was also observed in two lactogenic receptor-mediated bioassays most likely due to the elimination of the intermolecular hydrogen bond of Ser-184 with a side chain of Tyr-127, which appears in all lactogenic receptors.

The role of prolactin in realization of estradiol action in the uterus of ovariectomized rats

The aim of this study was to examine the role of prolactin (PRL) in promoting the effects of estradiol (E2) on the uterus. Ovariectomized rats were given a single injection of E2 dipropionate (10 micrograms/rat), along with injections of ovine prolactin (PRL; a single dose--2.5 IU/rat), or injections of metoclopramide (a single dose--0.5 mg/rat), or injections of bromocriptine (a single dose--0.25 mg/rat). The effects of E2 on the uterus were determined by measuring mitotic indexes; cell, nucleus and nucleolus volumes (morphometry), and DNA content (Feulgen's method) in luminal and glandular epithelia, endometrial stromal cells at 24, 36 and 48 h after the injection of E2. It is revealed that at each time point after E2 and PRL or metoclopramide treatment almost all the tested parameters were lower than those in control rats treated with E2 and distilled water. The values obtained in all the periods after E2 along with bromocriptine treatment were higher compared with those in E2-treated animals. Most of the results are statistically significant (P < 0.05-0.001). In the absence of E2 none of the drugs used influenced the uterine parameters tested. The effect of PRL is likely to be mediated by their receptors in the uterus, and it occurs by changing the mechanism of estrogen action in the uterus. The actions of metoclopramide and bromocriptine are probably also mediated by PRL.

Expression cloning of a cDNA encoding a fish prolactin receptor

By using an expression cloning strategy, we isolated a single positive clone encoding a tilapia prolactin (PRL) receptor. Tilapia PRL188 was used to screen a freshwater tilapia kidney expression library transfected in COS cells. The tilapia PRL receptor is a mature protein of 606 amino acids. The extracellular domain is devoid of the tandem repeat units present in birds and has two pairs of cysteine residues, a Trp-Ser-Xaa-Trp-Ser motif, and two potential N-glycosylation sites. The cytoplasmic domain contains 372 amino acids, including box 1, a sequence previously shown to be important for signal transduction in mammalian species. Thus, the general structure is similar to the long form of mammalian PRL receptors; however, amino acid comparisons reveal a rather low identity (approximately 37%). Northern blot analysis shows the existence of a single transcript in osmoregulatory tissues and reproductive organs. This localization is in agreement with known functions of PRL in teleosts.

Two forms of the prolactin receptor messenger ribonucleic acid are Present in ovine fetal liver and adult ovary

Previous binding studies indicated that there is little to no specific prolactin binding in ovine fetal liver and adult ovary. Therefore, we sought to determine if ovine prolactin receptor (PRLR) mRNA is present in those tissues. Primers were designed from the bovine PRLR cDNA sequence for use in reverse transcriptase-polymerase chain reaction (RT-PCR). RT-PCR analysis of ovine fetal liver total cellular RNA (tcRNA) isolated from days 60, 90, 105, 120 and 135 of gestation, and luteal tcRNA isolated from days 3, 7, 10, 13 and 16 of the estrous cycle revealed that PRLR mRNA was present in these tissues. However, two RT-PCR products were generated from both tissues. The two RT-PCR products did not differ between the two tissue sources in sequence, and were designated oPRLR-1 and oPRLR-2. Ovine PRLR-1 is 513 bp in length and is 96.4% identical to the bovine cDNA. Ovine PRLR-2 is identical to oPRLR-1 until nucleotide (nt) 420 at which point a 39 bp insertion occurs. This insertion occurs between Homology Boxes 1 and 2 within the cytoplasmic domain of the receptor, resulting in an 11 amino acid divergent sequence, followed by two stop codons. Ribonuclease-protection assay revealed that oPRLR-1 mRNA is the most abundant in these tissues. Our data indicate that two forms of oPRLR mRNA are Present in fetal liver and adult ovary, and that one form (oPRLR-2) is predicted to encode a truncated PRLR.

Localization of growth hormone receptor messenger RNA in human tissues

In order to identify GH target cells in human tissues, we investigated the celiuiar distribution of human GH receptor (GHR) messenger RNA. This was performed byin situ hybridization and Northern blot hybridization using complementary radioactive DNA probe encoding part of the extracellular domain of the GHR. Several tests were carried out to validate the detection of gene expression. Our results demonstrate that the GHR gene is expressed in all human tissues studied, including liver, muscle, kidney, heart, skin, thymus, adipose tissue, placenta, testis, ovary and mammary gland. The quantification of thein situ hybridization signal by densitometric analysis showed a greater expression of GHR transcript in liver, muscle, kidney, heart, and skin epidermis, and a reduced expression in thymus, mammary gland, testis, ovary, and dermis/ hypodermis. These results confirm the widespread distribution of the GHR gene expression in human tissues and identify the cells that might be responsive to GH.

Effects of somatotropin on the conceptus, uterus, and ovary during maternal recognition of pregnancy in cattle

Effects of recombinant bovine somatotropin (rbST) on ovarian and uterine function and the production of components of the insulin-like growth factor (IGF) system were examined during the period of maternal recognition of pregnancy in cattle. Lactating dairy cows were treated with 25 mg/d rbST (n = 8) or saline (n = 8) for 16 d after estrus. Ovaries, uteri, and conceptuses were collected on Day 17 after estrus. The length (millimeters) of the conceptus was recorded. The concentration of IGF-I and the content of IGF-binding proteins (BP) in uterine flushings were determined. Corpora lutea (CL) were weighed, and the number of follicles (> or = 2 mm in diameter) were counted. Follicular fluid from the largest and second-largest follicles was assayed for the concentration of IGF-I, IGFBP, progesterone, and estradiol. The length of the conceptus and the total amount of IGF-I in uterine fluid were similar for rbST and control. Recombinant bST increased 1) the weight of the CL, 2) the number of largest follicles (10 to 15 mm in diameter), 3) the concentration of IGF-I in the follicular fluid, 4) the follicular fluid content of IGFBP of the largest estrogenic follicle, and 5) the quantity of IGFBP in uterine flushings. The concentration of progesterone in the follicular fluid tended to be increased in rbST-treated cows, whereas the concentration of estradiol was similar to that of control cows. The concentration of progesterone in plasma was similar for rbST compared with control. In conclusion, the administration of rbST in lactating dairy cows for 16 d after estrus did not alter the growth of the conceptus collected on Day 17. The greatest responses to rbST were found within the ovary, where rbST increased the weight of the CL and altered the amount of IGF-I and IGFBP in the follicular fluid.

Characterization of human endometrial glycogen synthase

OBJECTIVE

To characterize and compare human endometrial glycogen synthase complementary DNA (cDNA) to the published rat liver and human skeletal muscle glycogen synthase transcripts and then to determine whether P-induced glycogen accumulation in endometrium is accompanied by a rise in glycogen synthase transcripts.

DESIGN

We performed bidirectional sequencing of segments of endometrial glycogen synthase with chosen primers. Endometrial tissue was cultured up to 72 hours with and without P. Total RNA was extracted from in vivo and cultured endometrium and used as template for semiquantitative reverse transcription polymerase chain reaction.

SETTING

Normal human volunteers in an academic research environment.

PATIENTS

Premenopausal women with histologically normal endometrium undergoing hysterectomy.

INTERVENTIONS

ENdometrium was maintained in culture with and without exposure to P.

MAIN OUTCOME MEASURE

Human endometrial glycogen synthase cDNA nucleotide sequence and messenger RNA (mRNA) levels.

RESULTS

In all areas sequenced, human endometrial glycogen synthase cDNA is identical to that of human skeletal muscle. Conversely, it is only 80% similar to rat and human liver glycogen synthase cDNA in these areas. Tissue levels of glycogen synthase transcript did not change in vivo or in vitro after P exposure.

CONCLUSIONS

Human endometrial glycogen synthase is similar if not identical to human skeletal muscle glycogen synthase. The mechanism for P induction of endometrial glycogen does not require change in the concentration of glycogen synthase transcripts.

Expression of two isoforms of the human growth hormone receptor in normal liver and hepatocarcinoma

In man, two isoforms of growth hormone receptor (GHR) have been reported. The first, hGHR corresponds to the original form described by Leung et al. (J. Biol. Chem. 264 (1987) 9905-9910). The second, hGHRd3, missing 22 N-terminal amino acids is encoded by an mRNA derived from alternative splicing and deletion of the third exon. This latter form has been isolated from placenta and its tissue distribution, as well its function warrant further examination. We studied the relative expression of the two isoforms of GHR in liver at various stages of development of differentiation. Several samples from fetal livers and hepatocarcinomas were analysed and we observed that hGHR and hGHRd3 can be expressed solely or coordinately. Furthermore, we investigated the possibility that alternative splicing of exon 3 could be related to the specific use of different promoters. Our data show that both isoforms have identical 5'-untranslated regions in normal liver or in hepatoma cell lines. Finally, these experiments strongly suggest that hGHRd3 is efficiently translated as a functional receptor, with the soluble form of GHR being recovered in the cell media. The results of the present study support the concept that both isoforms are expressed in human liver, with exon 3 alternative splicing being neither tissue specific nor related to hepatic differentiation.

Extended function of the corpus luteum and earlier development of the second follicular wave in heifers treated with bovine somatotropin

Effects of recombinant bovine somatotropin (bST) on growth of the corpus luteum (CL) and development of ovarian follicles were tested. Starting at estrus (Day=0), the following treatments were administered: control (saline injected Days 0 to 19, n=5); bST[0-9] (25 mg bST injected Days 0 to 9, saline injected Days 10 to 19, n=5); bST[10-19] (saline injected Days 0 to 9, 25 mg bST injected Days 10 to 19, n=5); and bST[0-19] (25 mg bST injected Days 0 to 19, n=6). Blood was collected daily for progesterone analysis, and ultrasound examinations were performed daily for measurement of follicles and CL. Compared with the heifers treated with saline, those treated with bST had larger CL and more progesterone during the early (</= Day 10) and late (Days 15 to 21) phases of the estrous cycle. At mid-cycle (Days 10 to 15), luteal tissue area and progesterone levels were similar for bST- and saline-treated heifers. Ovarian follicular growth was similar for bST- and saline-treated heifers during the first follicular wave. However, during recruitment for the second follicular wave (Days 10 to 14), second largest follicles emerged sooner (P<0.001), the number of Class-3 (>/=10 mm) follicles was greater (P<0.01) and largest follicles were smaller (P<0.001) in bST than in saline-treated heifers. Estrous cycle length and ovulation rate were similar for each group. In conclusion, bST increased initial development of the CL and extended its function. Furthermore, the second follicular wave was earlier with bST.

Cloning and sequencing of the cDNA encoding the murine mammary gland long-form prolactin receptor

The nucleotide sequence of a 1992-bp cDNA encoding the long form of the murine mammary prolactin receptor (PRL-R) has been determined. The deduced 68-kDa protein has high sequence identity with long forms of prolactin receptors from rat ovary and rabbit mammary gland.

Bovine placental prolactin-related hormones

The bovine placenta, like that of rodents and primates, synthesizes members of the PRL/GH gene family, which may assist the pituitary hormones or perform unique functions during pregnancy. Bovine placental lactogen (bPL) potentially may act through.three receptors: as an agonist or partial antagonist at the PRL and GH receptors, and via an apparently specific receptor in the endometrium. A large distinct subfamily of diverse primary structure, including bovine PRL-related protein I (bPRP-I), evidently does not act via these receptors. Advances in our understanding of hormone-receptor interactions for this gene family have provided new tools to study the role of these hormones in the successful pregnancy.